Zhuhai Rundu Pharmaceutical Co., Ltd.

Shenzhen Stock Exchange 002923.SZ

Zhuhai Rundu Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) on January 14, 2025: 2.29

Zhuhai Rundu Pharmaceutical Co., Ltd. Price to Sales Ratio (P/S) is 2.29 on January 14, 2025, a -20.23% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.

Zhuhai Rundu Pharmaceutical Co., Ltd. 52-week high Price to Sales Ratio (P/S) is 3.06 on March 06, 2024, which is 33.84% above the current Price to Sales Ratio (P/S).
Zhuhai Rundu Pharmaceutical Co., Ltd. 52-week low Price to Sales Ratio (P/S) is 1.78 on February 07, 2024, which is -22.23% below the current Price to Sales Ratio (P/S).
Zhuhai Rundu Pharmaceutical Co., Ltd. average Price to Sales Ratio (P/S) for the last 52 weeks is 2.43.

Key data

Date	Price to Sales Ratio (P/S)	Price to Book Ratio (P/B)	Dividend Yield	Free Cash Flow Yield

Shenzhen Stock Exchange: 002923.SZ

Zhuhai Rundu Pharmaceutical Co., Ltd.

CEO	Mr. Jie Liu
IPO Date	Jan. 5, 2018
Location	China
Headquarters	No. 6, North Airport Road
Employees	1,945
Sector	Health Care
Industries Pharmaceuticals

Description

Zhuhai Rundu Pharmaceutical Co., Ltd., a pharmaceutical company, develops, produces, and markets pharmaceutical ingredients for cardiovascular, gastrointestinal, CNS, and anesthesia areas in China and internationally. It offers APIs, intermediates, FDF, and pellets, as well as formulations in the forms of capsules, tablets, and injections. The company was founded in 1997 and is headquartered in Zhuhai, China.

Key trends

Past 5 years